Lo que Ya se presentó en ASCO :
Lurbinectedin Plus Irinotecan Is Safe, Prolongs Responses in High-Risk, Pretreated SCLC
Author(s):
Key Takeaways
- Lurbinectedin and irinotecan combination achieved a 43.6% overall response rate in high-risk SCLC patients.
- Median duration of response was 7.1 months, with a median progression-free survival of 4.7 months .
Second-line treatment with lurbinectedin and irinotecan displayed a favorable risk/benefit profile and produced high, durable response rates in high-risk patients with small cell lung cancer (SCLC), particularly those with a chemotherapy treatment-free interval (CTFI) of more than 30 days, according to data from the dose-expansion portion of the phase 1/2 study PM1183-A-014-15 study (NCT02611024).1
Findings presented during the 2024 ASCO Annual Meeting showed that the doublet produced a 43.6% (95% CI, 33.7%-53.8%) overall response rate by independent review committee (IRC) in the overall population (n = 101), and the median duration of response (DOR) was 7.1 months (95% CI, 4.6-9.4). The median progression-free survival (PFS) was 4.7 months (95% CI, 3.8-5.7) and the median overall survival (OS) was 9.6 months (95% CI, 7.8-13.4). Additionally, the OS rate at 12 months was 43.4% (95% CI, 33.4%-53.4%) . ...
1745P - How to optimize the response with trabectedin in soft tissue sarcomas? Data from a high-volume center.
- Sebastian Diaz (Seville, Spain)
1728P - Results of TNT: A phase 2 study using talimogene laherparepvec, nivolumab and trabectedin for advanced leiomyosarcoma and liposarcoma [NCT# 03886311]
- Sant P. Chawla (Santa Monica, United States of America, CA)
1729P - Update on SAINT: A Phase 2 Study using Trabectedin (T) in Combination with Ipilimumab (I) and Nivolumab (N) in previously Treated Soft Tissue Sarcoma
- Anmol Dia Agarwal (Santa Monica, United States of America)
196P - Randomized Phase II Study of Trabectedin/Olaparib Compared to Physician’s Choice in Subjects with Previously Treated Advanced or Recurrent Solid Tumors Harboring DNA Repair Deficiencies.
- Richard F. Schlenk (Heidelberg, Germany)
1739P - Linnovate: A phase 1/2 study of safety/efficacy using lurbinectedin combined with ipilimumab and nivolumab for advanced soft tissue sarcoma (NCT05876715): Interim analysis of phase 1 part
- Erlinda M. Gordon (Santa Monica, United States of America)
1790P - Phase 2 data of lurbinectedin (LUR) and irinotecan (IRI) in relapsed small cell lung cancer (SCLC) patients (pts) with chemotherapy-free interval (CTFI)>30 days (d)
- Jon Zugazagoitia (Madrid, Spain)
1798P - Relapsed and refractory systemic therapy real-world outcomes in the Canadian Small cell lung Cancer Database (CASCADE)
- Sara Moore (Ottawa, Canada)
1813TiP - Debio 0123, a highly selective WEE1 inhibitor, combined with carboplatin (CP) and etoposide (ETOP) in patients (pts) with small cell lung cancer (SCLC) that progressed after platinum-based therapy: a phase 1 dose escalation and expansion study
- Valentina Gambardella (Valencia, Spain, Valencia)
641P - Phase 1/2 Clinical and Pharmacokinetic Study of Ecubectedin in Combination with Irinotecan in Patients with Selected Advanced Solid Tumors
- Ana Gil Torralvo (Seville, Spain)
.jpeg)
.jpeg)